Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

This study has been terminated.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: February 8, 2008
Last updated: September 27, 2013
Last verified: September 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)